LAWRENCE, Kan. and DUBLIN, Ireland ? IdentiGEN Ltd.
, a leading provider of DNA-based solutions to the agriculture and food industries in Europe, today announced the formation of a new subsidiary, IdentiGEN North America, Inc.
, and the hiring of Donald R. Marvin
as president and chief executive officer.
pork. Donald Marvin, the new company's president and chief executive officer, has been a biotechnology entrepreneur and leader in the commercialization of new life sciences diagnostic and research technologies and products for more than 25 years.
He is currently president and CEO of Cairn Associates Inc., a life sciences strategy consulting and investment firm.
"We are especially pleased that our North American expansion will be led by Don Marvin, a life sciences executive with extensive experience in starting and growing entrepreneurial companies, who will direct our efforts to bring the benefits of our innovative identification
"The value that consumers place on IdentiGEN's unique and cost effective ability to help guarantee the origin and safety of the meat they buy has been demonstrated in Europe, where the TraceBack system has been operational since 2000," said Mr. Marvin
"My past experience in the human DNA identity and genetic variability testing business has given me a
first-hand appreciation of the power of 'nature's bar code', and I believe that our DNA-based TraceBack system offers a solution of unparalleled accuracy, simplicity and practicality that will enhance the safety and quality of our food supply and provide tangible benefits to the producers,
sellers and consumers of meat products.
Before founding Cairn Associates, Mr. Marvin was a co-founder of Nasdaq-traded Orchid BioSciences, a pioneer in human DNA identity testing,
served as its chief operating officer, chief financial officer and senior vice president of corporate development.
Previously, Mr. Marvin was president and CEO of Diatron Corporation, a biomedical company developing fluorescence-based instrument systems for the clinical diagnostics industry.
prior experience includes strategic planning, business
development, technical administration and operations at PepsiCo, Abbott Laboratories and Bayer AG, as well as domestic and international marketing and sales for the clinical diagnostics subsidiary of Boehringer Ingelheim.
is an experienced fund-raiser, having completed private and public financings that have raised over $250 million for his
Mr. Marvin currently serves on the Board of Directors of Tepnel Life Sciences PLC and Melior Discovery, Inc., and also participates in several angel investment groups.